Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
scVRD induction, bortezomib-melphalan ASCT, IRD consolidation, and lenalidomide maintenance for newly diagnosed elderly symptomatic multiple myeloma
jRCTs071180031Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, lenalidomide, dexamethasone, plerixafor, filgrastim and 2 more in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: Complete response rate after consolidation therapy. Started Nov 2017; status: completed.
02
Drugs
bortezomiblenalidomidedexamethasoneplerixaforfilgrastim
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs071180031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180031.